According to FutureWise analysis the market for cold agglutinin disease in 2023 is US$ 102.51 million, and is expected to reach US$ 421.18 million by 2031 at a CAGR of 19.30%.
Cold agglutinin disease is a rare form of acquired autoimmune haemolytic anaemia in which the immune system targets and destroys the body's own red blood cells as a result of being exposed to cold temperatures. Symptoms of cold agglutinin disease (CAD) include weariness, cold hands and feet, dizziness, headaches, pale complexion, dark urine, jaundice, chest discomfort, back pain, leg pain, diarrhoea, heart issues, and vomiting, and most persons with the disease develop haemolytic anaemia. Cold agglutinin disease (CAD) affects clonal B-cell lymphoproliferative cells and is a rare subtype of autoimmune haemolytic anaemia (AIHA). CAD affects 15-25 percent of AIHA patients and is most common in middle-aged and elderly adults. When clonal B lymphocytes from the bone marrow are subjected to freezing temperatures (0-4°C), they create autoantibodies that attach to erythrocytes, causing agglutination and subsequently immune-mediated haemolysis. Recently, Enjaymo (sutimlimab-jome) in February 2022 launhed the medication with the goal of lowering the requirement for red blood cell transfusions in adults with cold agglutinin illness due to haemolysis (CAD). It is the first and only FDA-approved therapy for coronary artery disease. This medicine works by preventing red blood cell breakdown. Increasing expenditure for healthcare infrastructure can futher propel the market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Cold Agglutinin Disease Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Cold Agglutinin Disease Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.